Plasma Activated Saline in Wound Treatment

Wound Heal Clinical Trial

Official title:

Application of Plasma Activated Saline in Wound Treatment

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05924867
• Other study ID #: XJYFY-2021ZD03
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 20, 2023
• Est. completion date: June 20, 2024

Study information

• Verified date: June 2023
• Source: First Affiliated Hospital Xi'an Jiaotong University
• Contact: Miao Runchen, PhD
• Phone: 0086-18229097849
• Email: miaozao91[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, open-label, randomized, parallel controlled clinical trial. The purpose of this study is to understand the application value of plasma-activated normal saline in the treatment of different types of wounds. The main questions it aims to answer are: 1. What is the effect of plasma activated normal saline in promoting wound healing of different types? 2. What is the safety of plasma activated normal saline in the treatment of wound surface? Subjects will be randomly divided into the intervention group and the control group. The intervention group will receive wound treatment with plasma activated normal saline, and the control group will receive routine dressing change treatment.

Description:

As the population ages and antibiotic resistance increases, the chance of co-infection of various types of wounds increases greatly, resulting in prolonged wounds healing and eventually leading to bloodstream infections caused by germs, which can develop into life-threatening sepsis in severe cases. Plasma active saline is rich in reactive oxygen groups (ROS) and reactive nitrogen groups (RNS). It has good anti-inflammatory effect and is a potential new material to control wound infection and promote wound healing. Therefore, the purpose of this study was to apply plasma-activated water to different types of wounds and evaluate the effect of plasma-activated water on promoting healing of different types of wounds. And security issues in the application process. This study is a prospective, open label, randomized, parallel controlled trial. This study is expected to include 162 subjects, including 46 patients with postoperative incision infection, 34 patients with postoperative incision fat liquefaction, and 82 patients with cutaneous infectious ulcer. The participants will be randomly divided into intervention group and control group by grouping randomized method. The intervention group will be treated with plasma activated water flushing and wet compress, and the control group will be treated with routine dressing change. The investigators will collect participants' wound conditions, blood, microbiological tests and other relevant indicators during treatment and follow-up. To analyze the efficacy and safety of plasma-activated saline in the treatment of different wounds, the investigators will use independent sample T-test and K-M methods to compare the efficacy of the two groups, use descriptive analysis to represent the type and frequency of adverse events.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 162
• Est. completion date: June 20, 2024
• Est. primary completion date: June 20, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

1. Inclusion Criteria

1. Group of postoperative incision infection

• Age =18 years old, =75 years old, gender unlimited.
• Clinical diagnosis of postoperative incision infection.
• Must be no significant risk of head trauma or closed injury to the chest and abdomen.
• Fully understand the study content and subjects' rights and interests, and sign the informed consent.

2. Group of postoperative incision fat liquefaction

• Age =18 years old, =75 years old, gender unlimited.
• Clinical diagnosis of postoperative incision fat liquefaction.
• Must be no incision infection or organ infection was involved in deep surgery, and no other serious complications occurred.
• Must be no significant risk of head trauma or closed injury to the chest and abdomen.
• Fully understand the study content and subjects' rights and interests, and sign the informed consent.

3. Group of infectious ulcers

• Age =18 years old, =75 years old, gender unlimited.
• Clinical diagnosis of superficial skin ulcer infection caused by various causes, which can have one or more wounds.
• The formation time of the wound surface exceeds 1 month.
• Fully understand the study content and subjects' rights and interests, and sign the informed consent.

2. Exclusion Criteria

• Allergic to multiple drugs, dressings, gels or materials used in this study.
• Functional injury of cardiopulmonary system, with obvious risk of craniocerebral trauma or severe closed injury of chest and abdomen.
• Severe malnutrition, hypoproteinemia, moderate to severe anemia.
• Pregnant or lactating women (lactating female subjects can still be included if they agree to stop breastfeeding during the treatment period and within one week after the last medication).
• Patients with active wound bleeding, poor mental condition and critical condition.
• Poor glycemic control of diabetes mellitus; Severe malnutrition, hypoproteinemia, moderate and severe anemia.
• The presence of inflammatory skin diseases, such as atopic dermatitis or eczema, that affect efficacy and safety evaluation.
• Poor glycemic control of diabetes mellitus; Severe malnutrition, severe cardiopulmonary disease, hypertension, widespread local necrosis requiring immediate toe amputation.
• Combined with anaerobic bacteria infection, wet gangrene, abdominal infection, hematogenous infection, and intra-articular infection.
• Ulcers caused by diabetic feet and malignant tumors.
• History of glucocorticoid use and anticoagulant drug use within 12 months before enrollment.
• History of immune disease or immunosuppressant use.
• Poor compliance due to cognitive impairment or mental illness.
• Any conditions that the investigator considered might increase the risk to the subject or affect the evaluation of efficacy.

Related Conditions & MeSH terms

• Wound
• Wound Heal
• Wound Infection
• Wounds and Injuries

Intervention

Other:
• plasma activated saline
The plasma activated normal saline used in the intervention was prepared by a self-made machine, and the safety of the plasma activated water produced by the machine has passed the national quality inspection.
• Routine nursing
For postoperative incision infection group and infected ulcer group, conventional dressing change treatment was given, namely chlorhexidine disinfectant washing, drainage and bandaging; For the fat liquefaction group, conventional treatment was given, namely negative pressure suction.

Locations

Country	Name	City	State
China	First Affiliated Hospital of Xian JiaotongUniversity	Xi'an	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
First Affiliated Hospital Xi'an Jiaotong University

Country where clinical trial is conducted

China, 

References & Publications (19)

Bernhardt T, Semmler ML, Schafer M, Bekeschus S, Emmert S, Boeckmann L. Plasma Medicine: Applications of Cold Atmospheric Pressure Plasma in Dermatology. Oxid Med Cell Longev. 2019 Sep 3;2019:3873928. doi: 10.1155/2019/3873928. eCollection 2019. — View Citation

Brany D, Dvorska D, Halasova E, Skovierova H. Cold Atmospheric Plasma: A Powerful Tool for Modern Medicine. Int J Mol Sci. 2020 Apr 22;21(8):2932. doi: 10.3390/ijms21082932. — View Citation

Cheng B, Jiang Y, Fu X, Hao D, Liu H, Liu Y, Huang Z, Tan Q, Wang L, Hu D, Yang Y, Han C, Cheng Z, Ran X, Li Y. Epidemiological characteristics and clinical analyses of chronic cutaneous wounds of inpatients in China: Prevention and control. Wound Repair Regen. 2020 Sep;28(5):623-630. doi: 10.1111/wrr.12825. Epub 2020 Jun 25. — View Citation

Jang Y, Bok J, Ahn DK, Kim CK, Kang JS. Human Trial for the Effect of Plasma-Activated Water Spray on Vaginal Cleaning in Patients with Bacterial Vaginosis. Med Sci (Basel). 2022 Jun 18;10(2):33. doi: 10.3390/medsci10020033. — View Citation

Kadam S, Shai S, Shahane A, Kaushik KS. Recent Advances in Non-Conventional Antimicrobial Approaches for Chronic Wound Biofilms: Have We Found the 'Chink in the Armor'? Biomedicines. 2019 Apr 30;7(2):35. doi: 10.3390/biomedicines7020035. — View Citation

Kim S, Kim CH. Applications of Plasma-Activated Liquid in the Medical Field. Biomedicines. 2021 Nov 16;9(11):1700. doi: 10.3390/biomedicines9111700. — View Citation

Lee HR, Kang SU, Kim HJ, Ji EJ, Yun JH, Kim S, Jang JY, Shin YS, Kim CH. Liquid plasma as a treatment for cutaneous wound healing through regulation of redox metabolism. Cell Death Dis. 2023 Feb 13;14(2):119. doi: 10.1038/s41419-023-05610-9. — View Citation

Leren L, Johansen EA, Eide H, Sorum Falk R, Ljosa TM. Prevalence and factors associated with ulcer-related pain in persons with chronic leg ulcers-an explorative study. J Clin Nurs. 2021 Sep;30(17-18):2732-2741. doi: 10.1111/jocn.15787. Epub 2021 May 5. — View Citation

Liu HR, Yang P, Han S, Zhang Y, Zhu HY. The application of enhanced recovery after surgery and negative-pressure wound therapy in the perioperative period of elderly patients with colorectal cancer. BMC Surg. 2021 Sep 6;21(1):336. doi: 10.1186/s12893-021- — View Citation

Liu Z, Dumville JC, Norman G, Westby MJ, Blazeby J, McFarlane E, Welton NJ, O'Connor L, Cawthorne J, George RP, Crosbie EJ, Rithalia AD, Cheng HY. Intraoperative interventions for preventing surgical site infection: an overview of Cochrane Reviews. Cochra — View Citation

Mirhaj M, Labbaf S, Tavakoli M, Seifalian A. An Overview on the Recent Advances in the Treatment of Infected Wounds: Antibacterial Wound Dressings. Macromol Biosci. 2022 Jul;22(7):e2200014. doi: 10.1002/mabi.202200014. Epub 2022 Apr 28. — View Citation

Rezaei F, Vanraes P, Nikiforov A, Morent R, De Geyter N. Applications of Plasma-Liquid Systems: A Review. Materials (Basel). 2019 Aug 27;12(17):2751. doi: 10.3390/ma12172751. — View Citation

Seidel D, Diedrich S, Herrle F, Thielemann H, Marusch F, Schirren R, Talaulicar R, Gehrig T, Lehwald-Tywuschik N, Glanemann M, Bunse J, Huttemann M, Braumann C, Heizmann O, Miserez M, Kronert T, Gretschel S, Lefering R. Negative Pressure Wound Therapy vs — View Citation

Sen CK. Human Wound and Its Burden: Updated 2020 Compendium of Estimates. Adv Wound Care (New Rochelle). 2021 May;10(5):281-292. doi: 10.1089/wound.2021.0026. — View Citation

Smolkova B, Frtus A, Uzhytchak M, Lunova M, Kubinova S, Dejneka A, Lunov O. Critical Analysis of Non-Thermal Plasma-Driven Modulation of Immune Cells from Clinical Perspective. Int J Mol Sci. 2020 Aug 28;21(17):6226. doi: 10.3390/ijms21176226. — View Citation

Tanaka H, Bekeschus S, Yan D, Hori M, Keidar M, Laroussi M. Plasma-Treated Solutions (PTS) in Cancer Therapy. Cancers (Basel). 2021 Apr 6;13(7):1737. doi: 10.3390/cancers13071737. — View Citation

Xu D, Wang S, Li B, Qi M, Feng R, Li Q, Zhang H, Chen H, Kong MG. Effects of Plasma-Activated Water on Skin Wound Healing in Mice. Microorganisms. 2020 Jul 21;8(7):1091. doi: 10.3390/microorganisms8071091. — View Citation

Zhai S, Xu M, Li Q, Guo K, Chen H, Kong MG, Xia Y. Successful Treatment of Vitiligo with Cold Atmospheric Plasma-Activated Hydrogel. J Invest Dermatol. 2021 Nov;141(11):2710-2719.e6. doi: 10.1016/j.jid.2021.04.019. Epub 2021 May 21. — View Citation

Zhang J, Qu K, Zhang X, Wang B, Wang W, Bi J, Zhang S, Li Z, Kong MG, Liu D, Liu C. Discharge Plasma-Activated Saline Protects Against Abdominal Sepsis by Promoting Bacterial Clearance. Shock. 2019 Jul;52(1):92-101. doi: 10.1097/SHK.0000000000001232. — View Citation

* Note: There are 19 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The trends in wound healing rate	Wound healing rate=Number of healing cases/total cases ×100%	1 day up to 21 days
Secondary	The number of participants with wound effusion	Observe whether there is fluid, pus and other exudation on the wound and the number of days when the effusion disappeared will be recorded.	The indicators will be collected at day 1, 7, 14 and 21 after the start of treatment
Secondary	The number of participants who tested positive for the etiology of wound exudates or extracts	Check whether there is bacterial infection and infected strains on the wound.	The indicators will be collected at day 1, 7, 14 and 21 after the start of treatment.
Secondary	Wound pain score	Wound pain will be measured on the Visual Analogue Scale with a minimum score of 0 and a maximum score of 10 on the VAS, 0 indicating no pain at all, 10 indicating severe pain that is unbearable, and a higher score indicating more severe pain.	The indicators will be collected at day 1, 7, 14 and 21 after the start of treatment.
Secondary	The number of adverse event	In this trial, any adverse medical event occurring within 30 days after the subject's signing of the informed consent to the final dose, regardless of whether there is a causal relationship with the test drug, is considered to be an adverse event. Adverse events and descriptions of all associated symptoms, such as time of occurrence, severity, duration, action taken, final outcome and outcome, will be recorded.	These indicators will be collected at 1, 7, 14, and 21 days after starting treatment, and at 1 week and 1 month after ending treatment.